More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.